

## Isis Pharmaceuticals Conference Call Notice

June 30, 2008

-- Tuesday, July 1, 2008

-- 10:00 a.m. EDT, 7:00 a.m. PDT

-- 877-548-7901

-- <http://www.isispharm.com>

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals (Nasdaq: ISIS) will conduct a conference call at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, July 1, to discuss results of the TV-1102 clinical trial and the ATL / TEVA / Isis relationship.

-- ATL and TEVA announced clinical data on TV-1102 demonstrating positive disease benefit in patients with multiple sclerosis

-- Isis to received \$1.3 million of ATL's \$4 million milestone payment from TEVA

-- Isis may receive one third of up to \$100 million in milestones

To view the press release  
Please visit <http://www.isispharm.com> or  
[http://www.antisense.com.au/\\_home.asp](http://www.antisense.com.au/_home.asp) to view the release titled:  
Teva Pharmaceuticals & Antisense Therapeutics Announce That ATL/TV 1102,  
a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis  
Demonstrated Significant Reduction in Disease Activity

To access this call via telephone

Please call 1-877-548-7901 in the United States, five to ten minutes prior to the call. You will be asked to provide your name and indicate that you wish to participate in the Isis Pharmaceuticals' conference call hosted by Dr. Stanley Crooke.

To access this call via internet:

Please go to the Isis website at <http://www.isispharm.com> five to ten minutes prior to the call and click on the Webcast icon on our Home Page.

This webcast will remain posted on Isis' website for a limited time.

SOURCE Isis Pharmaceuticals

-0- 06/30/2008

/CONTACT: Kristina Lemonidis, Associate Director, Corporate Development,  
+1-760-603-2490, or Amy Blackley, Ph.D., Manager, Corporate Development,  
+1-760-603-2772, both of Isis Pharmaceuticals/  
/Web site: <http://www.isispharm.com> /  
(ISIS) □

CO: Isis Pharmaceuticals

ST: California

IN: HEA BIO

SU: CCA TRI

AX-SB □

-- LAM067 --

6312 06/30/2008 10:00 EDT <http://www.prnewswire.com>